Hepion Pharmaceuticals Stock Price on May 13, 2024
HEPA Stock | USD 0.66 0.03 4.35% |
Below is the normalized historical share price chart for Hepion Pharmaceuticals extending back to February 10, 2014. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Hepion Pharmaceuticals stands at 0.66, as last reported on the 25th of November, with the highest price reaching 0.71 and the lowest price hitting 0.66 during the day.
If you're considering investing in Hepion Stock, it is important to understand the factors that can impact its price. Hepion Pharmaceuticals holds Efficiency (Sharpe) Ratio of -0.0252, which attests that the entity had a -0.0252% return per unit of risk over the last 3 months. Hepion Pharmaceuticals exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Hepion Pharmaceuticals' Risk Adjusted Performance of (0.02), market risk adjusted performance of (0.14), and Standard Deviation of 5.52 to validate the risk estimate we provide.
At present, Hepion Pharmaceuticals' Common Stock Total Equity is projected to increase significantly based on the last few years of reporting. The current year's Common Stock Shares Outstanding is expected to grow to about 4.2 M, whereas Total Stockholder Equity is forecasted to decline to about 6.9 M. . At present, Hepion Pharmaceuticals' Price Book Value Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price To Book Ratio is expected to grow to 1.86, whereas Price Earnings Ratio is forecasted to decline to (0.28). Hepion Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 11th of February 2014 | 200 Day MA 1.243 | 50 Day MA 0.6637 | Beta 1.813 |
Hepion |
Sharpe Ratio = -0.0252
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | HEPA |
Estimated Market Risk
5.49 actual daily | 48 52% of assets are more volatile |
Expected Return
-0.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Hepion Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Hepion Pharmaceuticals by adding Hepion Pharmaceuticals to a well-diversified portfolio.
Price Book 2.1125 | Book Value 1.159 | Enterprise Value 7 M | Enterprise Value Ebitda (0.1) | Shares Float 5.3 M |
Related Headline
AVROBIO Headline on 13th of May 2024
AVRO Stock Earnings Avrobio Beats EPS for Q1 2024 by investorplace.com
AVRO stock results show that Avrobio beat analyst estimates for earnings per share the first quarter of 2024.
Hepion Pharmaceuticals Valuation on May 13, 2024
It is possible to determine the worth of Hepion Pharmaceuticals on a given historical date. On May 13, 2024 Hepion was worth 1.26 at the beginning of the trading date compared to the closed value of 1.21. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Hepion Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Hepion Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Hepion Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Hepion Pharmaceuticals' related companies.
Open | High | Low | Close | Volume | |
1.29 | 1.38 | 1.19 | 1.26 | 89,451 | |
05/13/2024 | 1.26 | 1.26 | 1.18 | 1.21 | 35,436 |
1.18 | 1.31 | 1.18 | 1.29 | 49,437 |
Backtest Hepion Pharmaceuticals | | | Hepion Pharmaceuticals History | | | Hepion Pharmaceuticals Valuation | Previous | Next |
Hepion Pharmaceuticals Trading Date Momentum on May 13, 2024
On May 14 2024 Hepion Pharmaceuticals was traded for 1.29 at the closing time. The top price for the day was 1.31 and the lowest listed price was 1.18 . The trading volume for the day was 49.4 K. The trading history from May 14, 2024 was a factor to the next trading day price jump. The trading delta at closing time against the next closing price was 6.61% . The trading delta at closing time against the current closing price is 4.96% . |
Hepion Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Hepion Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Hepion Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Hepion financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Hepion Pharmaceuticals Stock history
Hepion Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Hepion is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Hepion Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Hepion Pharmaceuticals stock prices may prove useful in developing a viable investing in Hepion Pharmaceuticals
Last Reported | Projected for Next Year | ||
Common Stock Shares Outstanding | 4 M | 4.2 M | |
Net Loss | -40.8 M | -38.8 M |
Hepion Pharmaceuticals Quarterly Net Working Capital |
|
Hepion Pharmaceuticals Stock Technical Analysis
Hepion Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Hepion Pharmaceuticals Period Price Range
Low | November 25, 2024
| High |
0.00 | 0.00 |
Hepion Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Hepion Pharmaceuticals November 25, 2024 Market Strength
Market strength indicators help investors to evaluate how Hepion Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Hepion Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Hepion Pharmaceuticals stock market strength indicators, traders can identify Hepion Pharmaceuticals entry and exit signals to maximize returns
Hepion Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Hepion Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Hepion Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Hepion to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Risk Adjusted Performance | (0.02) | |||
Jensen Alpha | (0.35) | |||
Total Risk Alpha | (1.06) | |||
Treynor Ratio | (0.15) |
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Complementary Tools for Hepion Stock analysis
When running Hepion Pharmaceuticals' price analysis, check to measure Hepion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hepion Pharmaceuticals is operating at the current time. Most of Hepion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hepion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hepion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hepion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |